- Home
- CYTO vs CYCC Comparison
CYTO vs CYCC Comparison
Compare CYTO & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYTO
- CYCC
- Stock Information
- Founded
- CYTO 2003
- CYCC 1992
- Country
- CYTO Bermuda
- CYCC United States
- Employees
- CYTO N/A
- CYCC N/A
- Industry
- CYTO Biotechnology: Pharmaceutical Preparations
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- CYTO Health Care
- CYCC Health Care
- Exchange
- CYTO Nasdaq
- CYCC Nasdaq
- Market Cap
- CYTO 2.0M
- CYCC 2.3M
- IPO Year
- CYTO N/A
- CYCC N/A
- Fundamental
- Price
- CYTO $0.41
- CYCC $0.34
- Analyst Decision
- CYTO
- CYCC Buy
- Analyst Count
- CYTO 0
- CYCC 2
- Target Price
- CYTO N/A
- CYCC $11.00
- AVG Volume (30 Days)
- CYTO 182.2K
- CYCC 431.0K
- Earning Date
- CYTO 09-24-2024
- CYCC 11-12-2024
- Dividend Yield
- CYTO N/A
- CYCC N/A
- EPS Growth
- CYTO N/A
- CYCC N/A
- EPS
- CYTO N/A
- CYCC N/A
- Revenue
- CYTO N/A
- CYCC $74,000.00
- Revenue This Year
- CYTO N/A
- CYCC N/A
- Revenue Next Year
- CYTO N/A
- CYCC $88.68
- P/E Ratio
- CYTO N/A
- CYCC N/A
- Revenue Growth
- CYTO N/A
- CYCC N/A
- 52 Week Low
- CYTO $0.40
- CYCC $0.32
- 52 Week High
- CYTO $3.60
- CYCC $4.00
- Technical
- Relative Strength Index (RSI)
- CYTO 43.48
- CYCC 37.88
- Support Level
- CYTO $0.40
- CYCC $0.33
- Resistance Level
- CYTO $0.58
- CYCC $0.42
- Average True Range (ATR)
- CYTO 0.06
- CYCC 0.04
- MACD
- CYTO 0.00
- CYCC 0.01
- Stochastic Oscillator
- CYTO 17.14
- CYCC 8.21
About CYTO Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. The company's OligoPhore / SemaPhore platform is a versatile system that allows the complexation of therapeutic RNAs with a proprietary peptide to form a nanoparticle formulation. This formulation allows to deliver of therapeutic RNA by systemic administration to tissues affected by leaky vasculature, a hallmark of solid tumors and certain inflammatory conditions.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.